# Laboratory Corporation of America Holdings – Consensus ‘buy’ rating and 17.9% Upside Potential

- Link: https://www.directorstalkinterviews.com/laboratory-corporation-of-america-holdings-consensus-buy-rating-and-17.9-upside-potential/4121132397
- Published: 2023-11-09T14:05:58+00:00
- Author: Charlotte Edwards

**Laboratory Corporation of America Holdings** with ticker code (LH) now have 13
market analysts covering the stock. The analyst consensus now points to a rating
of ‘buy’. The range between the high target price and low target price is between
$270.00 and $210.00 and has a mean target at $244.08. Given that the stocks previous
close was at $206.97 and the analysts are correct then we can expect a percentage
increase in value of 17.9%. The 50 day moving average now sits at $203.08 and the
200 day MA is $202.59. The company has a market cap of 17.48B. The current share
price for the company is: $205.84 USD

 The potential market cap would be $20,609,252,687 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 21.18, revenue per share of $171.07
and a 5.33% return on assets.

Laboratory Corporation of America Holdings is a global life sciences company. The
Company provides information to help doctors, hospitals, pharmaceutical companies,
researchers, and patients make decisions. The Company’s segments include Labcorp
Diagnostics (Dx) and Labcorp Drug Development (DD). The Dx segment is an independent
clinical laboratory business. It offers a menu of frequently requested and specialty
diagnostic tests through an integrated network of primary and specialty laboratories
across the United States. In addition to diagnostic testing along with occupational
and wellness testing for employers and forensic DNA analysis, Dx segment also offers
a range of other testing services. The DD segment is a contract research organizations
business that provides end-to-end drug development services. The DD segment provides
these services predominantly to pharmaceutical, biotechnology and medical device
companies across the world. It serves clients in more than 100 countries.

Share on: